If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
January 4: Law amending Article 29 of Book I of the Labor and Social Welfare Code concerning maternity leave. March 19: Two-month fully paid maternity leave for schoolteachers and PTT employees is extended to all female civil servants. March 21: Law reforming the retirement schemes for workers in state industrial establishments — the rules differ based on the worker's sex and other factors. April 5: Social insurance law: includes specific provisions for salaried pregnant women and breastfeeding mothers, or those unable to breastfeed for medical reasons. December 28: Order establishing departmental committees for the aid and protection of immigrant women. July 3, 1929: Circular reorganizing hygiene clinics to ensure better sanitary oversight of prostitution. August 24, 1930: Decree enacting the Convention on the Nationality of Married Women (signed in Paris on September 12, 1928, between France and Belgium). December 9, 1931: Law granting female merchants eligibility to serve as judges in commercial courts. 1932
In pathology, a contracture is a shortening of muscles, tendons, skin, and nearby soft tissues that causes the joints to shorten and become very stiff, preventing normal movement. A contracture is usually permanent, but less commonly can be temporary (such as in McArdle disease), or resolve over time but reoccur later in life (such as in Bethlem myopathy 1). It is usually in response to prolonged hypertonic spasticity in a concentrated muscle area, such as is seen in the tightest muscles of people with conditions like spastic cerebral palsy, but can also be due to the congenital abnormal development of muscles and connective tissue in the womb. Contractures develop usually when normally elastic tissues such as muscles or tendons are replaced by inelastic tissues (fibrosis). This results in the shortening and hardening of these tissues, ultimately causing rigidity, joint deformities and a total loss of movement around the joint. Most of the physical therapy, occupational therapy and other exercise regimens targeted towards people with spasticity focuses on trying to prevent contractures from happening in the first place. However, research on sustained traction of connective tissue in approaches such as adaptive yoga has demonstrated that contracture can be reduced at the same time that tendency toward spasticity is addressed.
=== Mechanical consideration === Muscle degeneration from rhabdomyolysis destroys the myosin and actin filaments in the affected tissue. This initiates the body's natural reaction to increasing perfusion to the area allowing for an influx of specialized cells to repair the injury. However, the swelling increases the intracellular pressure beyond normal limits. As the pressure builds in the muscle tissue, the surrounding tissue is crushed against the underlying tissue and bone. This is known as compartment syndrome which leads to greater death of the surrounding muscle tissue around the injury. As the muscle dies this will cause pain to radiate from the affected area into the compartmentalized tissue. A loss of range of motion from swelling will also be seen in the affected limb. Along with muscle strength weakness associated with the muscles involved from loss of filament interaction.
Key functions of the USSR were highly centralized in Moscow until its final years, despite its nominal structure as a federation of republics; the light decentralization reforms during the era of perestroika (restructuring) and glasnost (openness) conducted by Mikhail Gorbachev as part of the Helsinki Accords are cited as one of the factors which led to the dissolution of the USSR in 1991 as a result of the Cold War and the creation of the Commonwealth of Independent States. The Karelo-Finnish Soviet Socialist Republic, a relic of the Soviet-Finnish War (the Winter War), became the only union republic to be deprived of its status in 1956. The decision to downgrade Karelia to an autonomous republic within the Russian SFSR was made unilaterally by the central government without consulting its population. The official basis for downgrading the status of the republic was the changes that had occurred in the national composition of its population (about 80% of the inhabitants were Russians, Belarusians and Ukrainians), as well as the need to reduce the state apparatus, the cost of maintaining which in 1955 amounted to 19.6 million rubles.
Sources: en.wikipedia.org
Studies of 9/11's economic effects show the Manhattan office real-estate market and office employment were less affected than first feared, because of the financial services industry's need for face-to-face interaction. North American air space was closed for several days after the attacks and air travel decreased upon its reopening, leading to a nearly 20% cutback in air travel capacity, and exacerbating financial problems in the struggling U.S. airline industry. The September 11 attacks also led to the U.S. wars in Afghanistan and Iraq, as well as additional homeland security spending, totaling at least US$5 trillion.
== P == PAS – Positron annihilation spectroscopy Photoacoustic spectroscopy PAT or PACT – Photoacoustic tomography or photoacoustic computed tomography PAX – Photoemission of adsorbed xenon PC or PCS – Photocurrent spectroscopy Phase contrast microscopy PhD – Photoelectron diffraction PD – Photodesorption PDEIS – Potentiodynamic electrochemical impedance spectroscopy PDS – Photothermal deflection spectroscopy PED – Photoelectron diffraction PEELS – parallel electron energy loss spectroscopy PEEM – Photoemission electron microscopy (or photoelectron emission microscopy) PES – Photoelectron spectroscopy PINEM – photon-induced near-field electron microscopy PIGE – Particle (or proton) induced gamma-ray spectroscopy, see nuclear reaction analysis PIXE – Particle (or proton) induced X-ray spectroscopy PL – Photoluminescence Porosimetry Powder diffraction PTMS – Photothermal microspectroscopy PTS – Photothermal spectroscopy
Clascoterone, sold under the brand name Winlevi, is an antiandrogen medication which is used topically in the treatment of acne. The medication is used as a cream by application to the skin, for instance the face and scalp. Clascoterone is an antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone. It shows minimal systemic absorption when applied to skin. Clascoterone was developed by Cassiopea and was approved for medical use in the United States in August 2020 and in the European Union in October 2025. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
Korolev's conversion of his surplus Vostok capsules to the Voskhod spacecraft allowed the Soviet space program to beat the Gemini program in achieving the first spaceflight with a multi-person crew, and the first "spacewalk". Gemini took a year longer than planned to make its first flight, so Voskhod 1 became the first spaceflight with a three-person crew on October 12, 1964. The USSR touted another "technological achievement" during this mission: it was the first space flight during which cosmonauts performed in a shirt-sleeve-environment. However, flying without spacesuits was not due to safety improvements in the Soviet spacecraft's environmental systems; rather this was because the craft's limited cabin space did not allow for spacesuits. Flying without spacesuits exposed the cosmonauts to significant risk in the event of potentially fatal cabin depressurization. This was not repeated until the US Apollo Command Module flew in 1968; the command module cabin was designed to transport three astronauts in a low pressure, pure oxygen shirt-sleeve environment while in space. On March 18, 1965, about a week before the first piloted Project Gemini space flight, the USSR launched the two-cosmonaut Voskhod 2 mission with Pavel Belyayev and Alexei Leonov. Voskhod 2's design modifications included the addition of an inflatable airlock to allow for extravehicular activity (EVA), also known as a spacewalk, while keeping the cabin pressurized so that the capsule's electronics would not overheat. Leonov performed the first-ever EVA as part of the mission.
As of May 2021, Pakistan operates six licensed commercial nuclear power plants. The Pakistan Atomic Energy Commission (PAEC) oversees these plants, while the Pakistan Nuclear Regulatory Authority ensures their safe operation. These plants contribute approximately 5.8% to Pakistan's electricity supply, while fossil fuels (crude oil and natural gas) provide 64.2%, hydroelectric power provides 29.9%, and coal contributes 0.1%. The KANUPP-I, Pakistan's first commercial nuclear power plant, was supplied by Canada in 1971. Sino-Pakistani nuclear cooperation began in the 1980s, leading to the establishment of CHASNUPP-I. In 2005, both countries proposed a joint energy security plan, aiming for a generation capacity exceeding 160,000 MWe by 2030. Pakistan's Nuclear Energy Vision 2050 targets a capacity of 40,000 MWe, with 8,900 MWe expected by 2030. In June 2008, the nuclear complex at Chashma in Punjab Province expanded with the installation of Chashma-III and Chashma–IV reactors, each with 325–340 MWe, costing ₨129 billion, with ₨80 billion from international sources, mainly China. Another agreement for China's assistance was signed in October 2008, seen as a response to the US–India agreement. The project's cost was then US$1.7 billion, with a foreign loan of US$1.07 billion. In 2013, Pakistan established a second nuclear complex in Karachi with plans for additional reactors, similar to Chashma. Electrical energy in Pakistan is generated by various corporations and distributed evenly among the four provinces by the National Electric Power Regulatory Authority (NEPRA).
==== Serotonin binding to 5-HT2C ==== Serotonin is an endogenous non-selective agonist for the 5-HT2C receptor with a binding constant of Ki = 16.0 nM. When serotonin binds to the receptors, the most important contacts are in TM helixes 3, 5 and 6 (Figure 3), while the other four TM helixes do not interact directly with the serotonin compound. When binding of serotonin takes place, the protonated primary amine site forms a salt bridge with D134 residue in TM 3, as well as forming a hydrogen bond with residue S138 in TM 3. The aromatic indole ring forms a strong Van der Waals interaction with residues F223 in TM 5 and F328 in TM 6. The ring falls tight into the receptor pocket, stacked between two phenylalanines. Amine of the indole group forms a hydrogen bond with S219 residue in TM 5 and hydroxide substituent of the indole forms hydrogen bonds both with residue S131 in TM 3 and I332 in TM 6. There is also a strong Van der Waals interaction between the indole and I332 in TM 6.
In people with severe valvular disease, however, short-term risks of cardiovascular compromise after intramuscular injections may outweigh the benefits, and oral therapy may be considered instead of IM injections in this subset of patients. Diseases of the aortic root can cause chronic aortic regurgitation. These diseases include syphilitic aortitis, Behçet's disease, and reactive arthritis.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.